tiprankstipranks
Syndax Pharmaceuticals Inc. (DE:1T3)
NASDAQ:1T3
Germany Market
1T3
Syndax Pharmaceuticals
RESEARCH TOOLSreports

Syndax Pharmaceuticals (1T3) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

1T3 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Syndax
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1T3 Stock 12 Month Forecast

Average Price Target

€32.35
▲(61.19% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is €32.35 with a high forecast of €40.10 and a low forecast of €25.28. The average price target represents a 61.19% change from the last price of €20.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","41":"€41","14.75":"€14.75","23.5":"€23.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.09832788,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€40.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.34985872444445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.27938062,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,14.75,23.5,32.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.725,18.52294829846154,20.320896596923077,22.118844895384616,23.916793193846154,25.714741492307695,27.51268979076923,29.31063808923077,31.108586387692306,32.90653468615385,34.70448298461538,36.50243128307692,38.300379581538465,{"y":40.09832788,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.725,17.926912209572652,19.128824419145303,20.33073662871795,21.5326488382906,22.734561047863252,23.9364732574359,25.13838546700855,26.3402976765812,27.542209886153852,28.744122095726503,29.94603430529915,31.1479465148718,{"y":32.34985872444445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.725,17.38302927846154,18.04105855692308,18.699087835384617,19.357117113846154,20.01514639230769,20.673175670769233,21.33120494923077,21.989234227692307,22.64726350615385,23.305292784615386,23.963322063076923,24.621351341538464,{"y":25.27938062,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.485,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.725,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€40.10Average Price Target€32.35Lowest Price Target€25.28
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:1T3
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€34.87
Buy
73.73%
Upside
Reiterated
06/15/26
Syndax Buy Rating Reiterated as Revuforj Data Strengthens AML Profile; $40 Price Target Maintained
Stifel Nicolaus Analyst forecast on DE:1T3
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
€40.1
Buy
99.79%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on DE:1T3
Bradley Canino
Guggenheim
Guggenheim
€29.64→€27.02
Buy
34.64%
Upside
Reiterated
06/12/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from Guggenheim
Goldman Sachs Analyst forecast on DE:1T3
Corinne Johnson
Goldman Sachs
Goldman Sachs
€29.64
Buy
47.67%
Upside
Reiterated
06/03/26
Analyst Reiterates Buy on Syndax, Sees Durable Revuforj Upside with Unchanged $34 Price Target
Bank of America Securities Analyst forecast on DE:1T3
Jason Zemansky
Bank of America Securities
Bank of America Securities
€25.28
Buy
25.96%
Upside
Reiterated
05/21/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Syndax Pharmaceuticals (NASDAQ: SNDX) and Fresenius Medical Care (NYSE: FMS)
UBS Analyst forecast on DE:1T3
David Dai
UBS
UBS
€33.12→€32.25
Buy
60.70%
Upside
Reiterated
05/13/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from UBS
Jefferies Analyst forecast on DE:1T3
Faisal Khurshid
Jefferies
Jefferies
€34.87→€32.25
Buy
60.70%
Upside
Reiterated
05/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Barclays Analyst forecast on DE:1T3
Etzer Darout
Barclays
Barclays
€30.51→€32.25
Buy
60.70%
Upside
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Alignment Healthcare (ALHC), Syndax Pharmaceuticals (SNDX)
TD Cowen Analyst forecast on DE:1T3
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
Mizuho Securities Analyst forecast on DE:1T3
Salim Syed
Mizuho Securities
Mizuho Securities
€39.23→€37.48
Buy
86.76%
Upside
Reiterated
03/30/26
Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
J.P. Morgan Analyst forecast on DE:1T3
Anupam Rama
J.P. Morgan
J.P. Morgan
€28.77→€39.23
Buy
95.45%
Upside
Reiterated
03/09/26
Syndax price target raised to $45 from $33 at JPMorganSyndax price target raised to $45 from $33 at JPMorgan
Citi Analyst forecast on DE:1T3
Yigal Nochomovitz
Citi
Citi
€44.46→€49.69
Buy
147.57%
Upside
Reiterated
03/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from Citi
BTIG Analyst forecast on DE:1T3
Justin Zelin
BTIG
BTIG
€48.82
Buy
143.23%
Upside
Reiterated
01/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG
B. Riley Securities Analyst forecast on DE:1T3
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€28.77
Buy
43.33%
Upside
Reiterated
10/03/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities
Scotiabank Analyst forecast on DE:1T3
George Farmer
Scotiabank
Scotiabank
€14.82
Hold
-26.16%
Downside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:1T3
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€34.87
Buy
73.73%
Upside
Reiterated
06/15/26
Syndax Buy Rating Reiterated as Revuforj Data Strengthens AML Profile; $40 Price Target Maintained
Stifel Nicolaus Analyst forecast on DE:1T3
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
€40.1
Buy
99.79%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on DE:1T3
Bradley Canino
Guggenheim
Guggenheim
€29.64→€27.02
Buy
34.64%
Upside
Reiterated
06/12/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from Guggenheim
Goldman Sachs Analyst forecast on DE:1T3
Corinne Johnson
Goldman Sachs
Goldman Sachs
€29.64
Buy
47.67%
Upside
Reiterated
06/03/26
Analyst Reiterates Buy on Syndax, Sees Durable Revuforj Upside with Unchanged $34 Price Target
Bank of America Securities Analyst forecast on DE:1T3
Jason Zemansky
Bank of America Securities
Bank of America Securities
€25.28
Buy
25.96%
Upside
Reiterated
05/21/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Syndax Pharmaceuticals (NASDAQ: SNDX) and Fresenius Medical Care (NYSE: FMS)
UBS Analyst forecast on DE:1T3
David Dai
UBS
UBS
€33.12→€32.25
Buy
60.70%
Upside
Reiterated
05/13/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from UBS
Jefferies Analyst forecast on DE:1T3
Faisal Khurshid
Jefferies
Jefferies
€34.87→€32.25
Buy
60.70%
Upside
Reiterated
05/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)
Barclays Analyst forecast on DE:1T3
Etzer Darout
Barclays
Barclays
€30.51→€32.25
Buy
60.70%
Upside
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Alignment Healthcare (ALHC), Syndax Pharmaceuticals (SNDX)
TD Cowen Analyst forecast on DE:1T3
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
Mizuho Securities Analyst forecast on DE:1T3
Salim Syed
Mizuho Securities
Mizuho Securities
€39.23→€37.48
Buy
86.76%
Upside
Reiterated
03/30/26
Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
J.P. Morgan Analyst forecast on DE:1T3
Anupam Rama
J.P. Morgan
J.P. Morgan
€28.77→€39.23
Buy
95.45%
Upside
Reiterated
03/09/26
Syndax price target raised to $45 from $33 at JPMorganSyndax price target raised to $45 from $33 at JPMorgan
Citi Analyst forecast on DE:1T3
Yigal Nochomovitz
Citi
Citi
€44.46→€49.69
Buy
147.57%
Upside
Reiterated
03/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from Citi
BTIG Analyst forecast on DE:1T3
Justin Zelin
BTIG
BTIG
€48.82
Buy
143.23%
Upside
Reiterated
01/02/26
Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG
B. Riley Securities Analyst forecast on DE:1T3
Mayank Mamtani
B. Riley Securities
B. Riley Securities
€28.77
Buy
43.33%
Upside
Reiterated
10/03/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities
Scotiabank Analyst forecast on DE:1T3
George Farmer
Scotiabank
Scotiabank
€14.82
Hold
-26.16%
Downside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

3 Months
Phil NadeauTD Cowen
Success Rate
9/17 ratings generated profit
53%
Average Return
+12.52%
Copying Phil Nadeau's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +12.52% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
11/20 ratings generated profit
55%
Average Return
+6.67%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +6.67% per trade.
2 Years
Jason ZemanskyBank of America Securities
Success Rate
12/23 ratings generated profit
52%
Average Return
+16.35%
Copying Jason Zemansky's trades and holding each position for 2 Years would result in 52.17% of your transactions generating a profit, with an average return of +16.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1T3 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
11
11
9
12
14
Buy
7
5
6
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
16
15
16
18
In the current month, 1T3 has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1T3 average Analyst price target in the past 3 months is 32.35.
Each month's total comprises the sum of three months' worth of ratings.

1T3 Financial Forecast

1T3 Earnings Forecast

Next quarter’s earnings estimate for 1T3 is -€0.42 with a range of -€0.70 to -€0.29. The previous quarter’s EPS was -€0.42. 1T3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1T3 is -€0.42 with a range of -€0.70 to -€0.29. The previous quarter’s EPS was -€0.42. 1T3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.

1T3 Sales Forecast

Next quarter’s sales forecast for 1T3 is €68.90M with a range of €62.49M to €76.75M. The previous quarter’s sales results were €56.30M. 1T3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1T3 is €68.90M with a range of €62.49M to €76.75M. The previous quarter’s sales results were €56.30M. 1T3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.

1T3 Stock Forecast FAQ

What is DE:1T3’s average 12-month price target, according to analysts?
Based on analyst ratings, Syndax Pharmaceuticals Inc.’s 12-month average price target is 32.35.
    What is DE:1T3’s upside potential, based on the analysts’ average price target?
    Syndax Pharmaceuticals Inc. has 61.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Syndax Pharmaceuticals Inc. a Buy, Sell or Hold?
          Syndax Pharmaceuticals Inc. has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Syndax Pharmaceuticals Inc.’s share price target?
            The average share price target for Syndax Pharmaceuticals Inc. is 32.35. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €40.10 ,and the lowest forecast is €25.28. The average share price target represents 61.19% Increase from the current price of €20.07.
              What do analysts say about Syndax Pharmaceuticals Inc.?
              Syndax Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Syndax Pharmaceuticals Inc.?
                To buy shares of DE:1T3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.